Can small animal imaging accelerate drug development?

Journal of Cellular Biochemistry

Volumn , Issue SUPPL. 39, 2002, Pages 211-220

  Pomper, Martin G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell tracking; Drug development; Gene expression imaging; Molecular imaging; Small animal imaging

Indexed keywords

ANIMAL; ARTICLE; CANCER GENETICS; CANCER SUSCEPTIBILITY; DRUG RESEARCH; GENE MAPPING; GENETIC MODEL; GENETIC PREDISPOSITION; HUMAN; HUMAN GENOME; IMAGE RECONSTRUCTION; IMAGING; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG DESIGN; EXPERIMENTAL ANIMAL; REVIEW;

ANIMALIA;

ANIMALS; ANIMALS, LABORATORY; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS;

EID: 0036984115     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10443     Document Type: Article

References (33)

1. Aboagye EO, Price PM, Jones T. 2001. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov Today 6:293-302.
2. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M. 2001. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 3:143-153.
3. Bluemke DA, Stillman AE, Bis KG, Grist TM, Baum RA, D'Agostino R, Malden ES, Pierro JA, Yucel EK. 2001. Carotid MR angiography: Phase II study of safety and efficacy for MS-325. Radiology 219:114-122.
4. Brady F, Luthra SK, Brown GD, Osman S, Aboagye E, Saleem A, Price PM. 2001. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. Curr Pharm Des 7:1863-1892.
5. Buckley RH. 2002. Gene therapy for SCID - A complication after remarkable progress. Lancet 360:1185-1186.
6. Bulte JW, Duncan ID, Frank JA. 2002. In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J Cereb Blood Flow Metab 22:899-907.
7. Chatziioannou AF. 2002. Molecular imaging of small animals with dedicated PET tomographs. Eur J Nucl Med Mol Imaging 29:98-114.
8. Contag CH, Ross BD. 2002. It's not just about anatomy: In vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging 16:378-387.
9. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, Bares R. 2002. Early changes in [(18)F]FLT uptake after chemotherapy: An experimental study. Eur J Nucl Med Mol Imaging 29:1462-1469.
10. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566.
11. Eckelman WC, Waterhouse R, Frank R. 2001. Nuclear imaging and biomarkers in drug development using approved radiopharmaceuticals. J Clin Pharmacol Suppl 41:4S-6S.
12. Fowler JS, Volkow ND, Wang GJ, Ding YS, Dewey SL. 1999. PET and drug research and development. J Nucl Med 40:1154-1163.
13. Gibson RE, Burns HD, Eckelman WC. 1993. The potential uses of radiopharmaceuticals in the pharmaceutical industry. In: Burns HD, Gibson R, Dannals R, Siegl P, editors. Nuclear imaging in drug discovery, development, and approval. Boston: Birkhauser. p 321-331.
14. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. 2002. MRI of the tumor microenvironment. J Magn Reson Imaging 16:430-450.
15. Gregory SG, Sekhon M, Schein J, Zhao S, Osoegawa K, Scott CE, Evans RS, Burridge PW, Cox TV, Fox CA, Hutton RD, Mullenger IR, Phillips KJ, Smith J, Stalker J, Threadgold GJ, Birney E, Wylie K, Chinwalla A, Wallis J, Hillier L, Carter J, Gaige T, Jaeger S, Kremitzki C, Layman D, Maas J, McGrane R, Mead K, Walker R, Jones S, Smith M, Asano J, Bosdet I, Chan S, Chittaranjan S, Chiu R, Fjell C, Fuhrmann D, Girn N, Gray C, Guin R, Hsiao L, Krzywinski M, Kutsche R, Lee SS, Mathewson C, McLeavy C, Messervier S, Ness S, Pandoh P, Prabhu AL, Saeedi P, Smailus D, Spence L, Stott J, Taylor S, Terpstra W, Tsai M, Vardy J, Wye N, Yang G, Shatsman S, Ayodeji B, Geer K, Tsegaye G, Shvartsbeyn A, Gebregeorgis E, Krol M, Russell D, Overton L, Malek JA, Holmes M, Heaney M, Shetty J, Feldblyum T, Nierman WC, Catanese JJ, Hubbard T, Waterston RH, Rogers J, de Jong PJ, Fraser CM, Marra M, McPherson JD, Bentley DR. 2002. A physical map of the mouse genome. Nature 418:743-750.
16. Grunder G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, Szymanski S, Wilson PD, Howard DR, Wong DF. 1997. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 17:175-185.
17. Gupta N, Price PM, Aboagye EO. 2002. PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur J Cancer 38:2094.
18. Hietala J. 1999. Ligand-receptor interactions as studied by PET: Implications for drug development. Ann Med 31: 438-443.
19. Hoekstra CJ, Hoekstra OS, Stroobants SG, Vansteenkiste J, Nuyts J, Smit EF, Boers M, Twisk JW, Lammertsma AA. 2002. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 43:1304-1309.
20. Hogemann D, Josephson L, Weissleder R, Basilion JP. 2000. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug Chem 11:941-946.
21. Hume SP, Myers R. 2002. Dedicated small animal scanners: A new tool for drug development? Curr Pharm Des 8:1497-1511.
22. Kreider BL. 2001. Proteomics: Defining protein function in the post genomics era. In: Doherty AM, editor. Annual reports in medicinal chemistry. New York: Academic. p 227-235.
23. Luker GD, Sharma V, Pica CM, Dahlheimer JL, Li W, Ochesky J, Ryan CE, Piwnica-Worms H, Piwnica-Worms D. 2002. Noninvasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci USA 99:6961-6966.
24. MacBeath G, Schreiber SL. 2000. Printing proteins as microarrays for high-throughput function determination. Science 289:1760-1763.
25. Mayer-Kuckuk P, Banerjee D, Malhotra S, Doubrovin M, Iwamoto M, Akhurst T, Balatoni J, Bornmann W, Finn R, Larson S, Fong Y, Gelovani-Tjuvajev J, Blasberg R, Bertino JR. 2002. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: A method to modulate gene expression. Proc Natl Acad Sci USA 99:3400-3405.
26. Montelione GT. 2001. Structural genomics: An approach to the protein folding problem. Proc Natl Acad Sci USA 98:13488-13489.
27. Moore A, Josephson L, Bhorade RM, Basilion JP, Weissleder R. 2001. Human transferrin receptor gene as a marker gene for MR imaging. Radiology 221:244-250.
28. Paans AM, Vaalburg W. 2000. Positron emission tomography in drug development and drug evaluation. Curr Pharm Des 6:1583-1591.
29. Padhani AR, Ollivier L. 2001. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: Implications for diagnostic radiologists. Br J Radiol 74:983-986.
30. Pomper MG, Musachio JL, Scheffel U, Macdonald JE, McCarthy DJ, Reif DW, Villemagne VL, Yokoi F, Dannals RF, Wong DF. 2000. Radiolabeled neuronal nitric oxide synthase inhibitors: Synthesis, in vivo evaluation, and primate PET studies. J Nucl Med 41:1417-1425.
31. Rubin RH, Fischman AJ. 1997. Positron emission tomography in drug development. Q J Nucl Med 41:171-175.
32. Vaalburg W, Hendrikse NH, de Vries EF. 1999. Drug development, radiolabelled drugs and PET. Ann Med 31: 432-437.
33. Weissleder R. 2002. Scaling down imaging: Molecular mapping of cancer in mice. Nat Rev Cancer 2:11-18.